Hypofractionation for prostate cancer: a word of caution
Mené sur 820 patients atteints d'un cancer de la prostate de stade
Converging clinical evidence suggests that prostate cancer cells have a higher sensitivity to large radiotherapy fraction size than do normal tissues,1 implying that the use of hypofractionated radiotherapy schedules (>2 Gy per fraction) would improve the therapeutic ratio for patients with prostate cancer managed with external beam irradiation. Such improved therapeutic ratio, coupled with recent technical improvements in radiation planning and delivery allowing for better target conformality and reduced exposure of healthy tissues, makes hypofractionation an attractive treatment strategy for patients with prostate cancer.
The Lancet Oncology , commentaire, 2015